Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Sorafenib for FLT3-ITD-positive AML

Andreas Burchert • 3 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Sorafenib
SORMAIN

Most patients with FLT3-ITD-positive acute myeloid leukemia (AML), who relapse after allogenic stem cell transplantation (ASCT) succumb to their disease. Here, Andreas Burchert, MD, of the University of Marburg, Marburg, Germany, discusses the SORMAIN trial (EUDRACT 2010-018539-16) assessing whether FLT3-ITD inhibition with sorafenib can prevent AML relapse, thus improving the outlook for patients in remission following ASCT. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Prof. Burchert reveals the practice-changing results showing sorafenib maintenance therapy after ASCT is feasible and significantly enhances OS in patients with FLT3-ITD-positive AML.

More from Andreas Burchert

5:07
Optimizing transplantation outcomes for patients with AML
Andreas Burchert • 15 Oct 2021
5:00
Post-transplant maintenance strategies in AML
Andreas Burchert • 15 Oct 2021
2:57
Sorafenib as SOC maintenance after allo-transplant in FLT3+ AML
Andreas Burchert • 15 Oct 2021
1:44
The future of AML therapy
Andreas Burchert • 3 Jan 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals